search icon
      blog search icon

      Strata Skin Sciences Inc. (SSKN) stock is fluctuating. Here’s what has happened? - Stocks Telegraph

      By ST Staff

      Published on

      March 17, 2021

      12:57 PM UTC

      Strata Skin Sciences Inc. (SSKN) stock is fluctuating. Here’s what has happened? - Stocks Telegraph

      Strata Skin Sciences Inc. (NASDAQ: SSKN) stock declined by 5.50% in the last trading close while the SSKN stock rises by 21.16% during pre-market. Strata Skin Sciences is a medical technology company in dermatology and plastic surgery that focuses on designing, developing, and commercializing non-invasive tools to give additional information to the dermatologist during melanoma skin examinations.

      Recent Developments in SSKN

      • On 16 March, Strata Skin Sciences announced that the company is set to participate in an upcoming Lytham Partners Spring 2021 Investor Conference happening on March 30, 2020.
      • Another positive development for SSKN is that their independent study on the treatment of vitiligo Company’s XTRAC excimer laser got published in the Journal of The Euorpeon Academy of Dermatology and Venereology in the November 2020 issue.  For this, the study was done by a team of dermatologists in Japan and was approved by the Ethics Committee of Kansai Medical University Kori Hospital.

      According to the findings of the study, patients with refractory vitiligo including those who were previously unresponsive to traditional therapies such as topical steroids, excimer light, and narrowband UVB light achieved adequate repigmentation in five treatments. These patients were treated with the XTRAC excimer laser under a reduced blistering dose regimen, which offered greater therapeutic outcomes with less treatments than other UVB phototherapies.

      The higher irradiation rate of XTRAC relative to other available UVB phototherapies, ascribed better patient results in the research. Furthermore, the XTRAC treatments were well tolerated, and the use of a low blistering dose was shown to minimize the amount of treatment sessions required, easing the burden on patients and medical staff.

      Conclusion

      These recent developments in Strata Skin Sciences is visibly the reason behind the up and down in SSKN stock price. Investors seem to be interested in buying SSKN stock but it is clear that they are also being careful in making any long-term commitment.

      More From Stocks telegraph